TerminatedPhase 2ACTRN12611000931976

Telmisartan in the management of abdominal aortic aneurysm

The effects of Telmisartan, an angiotensinII type 1 receptor blocker, in reducing AAA growth in patients with abdominal aortic aneurysm.

Sponsor

James Cook University

Enrollment

300 participants

Start Date

Sep 9, 2011

Study Type

Interventional

Conditions

Abdominal Aortic Aneurysm

Summary

The primary purpose of the study is to investigate telmisartan as a novel therapy for patients with abdominal aortic aneurysms. We hypothesize that telmisartan will reduce AAA growth.

Eligibility

Sex: Both males and femalesMin Age: 40 YearssMax Age: 85 Yearss

Inclusion Criteria1

Written informed consent 2. Infra-renal AAA measuring a maximum orthogonal diameter greater than or equal to 35mm and less than or equal to 49mm on CTA or ultrasound; 3. Stable medication regime for the last 6 months; 4. No current indication for AAA repair according to the treating physician or expectation that this will be revised within the next year; 5. High likelihood of compliance with treatment over 24 months.

Exclusion Criteria1

Contraindications to study treatment, including: 1. renal impairment (i.e. creatinine >1.5x upper limit of normal [ULN]), 2. known significant renal stenosis (>70%) of one or both renal arteries, 3. chronic liver disease (i.e. cirrhosis or hepatitis) or abnormal liver function (i.e. ALT 1.5xULN), 4. electrolyte imbalance and 5. active gout; 6. Current or planned usage of an AT1 blocker 7. Current or planned usage of an ACE inhibitor. 8. If the patient has previously had abdominal aortic surgery

Interested in this trial?

Get notified about updates and connect with the research team.